Codexis Inc (CDXS)
3.46
-0.07
(-1.98%)
USD |
NASDAQ |
May 08, 16:00
3.46
0.00 (0.00%)
After-Hours: 20:00
Codexis Research and Development Expense (Quarterly): 11.25M for March 31, 2024
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 11.25M |
| December 31, 2023 | 11.23M |
| September 30, 2023 | 13.66M |
| June 30, 2023 | 17.33M |
| March 31, 2023 | 16.66M |
| December 31, 2022 | 19.69M |
| September 30, 2022 | 21.82M |
| June 30, 2022 | 19.09M |
| March 31, 2022 | 19.50M |
| December 31, 2021 | 16.36M |
| September 30, 2021 | 15.16M |
| June 30, 2021 | 12.83M |
| March 31, 2021 | 11.57M |
| December 31, 2020 | 10.36M |
| September 30, 2020 | 12.01M |
| June 30, 2020 | 10.85M |
| March 31, 2020 | 10.97M |
| December 31, 2019 | 8.873M |
| September 30, 2019 | 8.711M |
| June 30, 2019 | 8.274M |
| March 31, 2019 | 8.016M |
| December 31, 2018 | 7.514M |
| September 30, 2018 | 7.917M |
| June 30, 2018 | 7.37M |
| March 31, 2018 | 7.178M |
| Date | Value |
|---|---|
| December 31, 2017 | 9.417M |
| September 30, 2017 | 8.055M |
| June 30, 2017 | 6.348M |
| March 31, 2017 | 5.839M |
| December 31, 2016 | 5.964M |
| September 30, 2016 | 5.467M |
| June 30, 2016 | 5.112M |
| March 31, 2016 | 5.686M |
| December 31, 2015 | 5.216M |
| September 30, 2015 | 4.994M |
| June 30, 2015 | 5.17M |
| March 31, 2015 | 5.293M |
| December 31, 2014 | 5.047M |
| September 30, 2014 | 5.038M |
| June 30, 2014 | 7.733M |
| March 31, 2014 | 4.834M |
| December 31, 2013 | 8.83M |
| September 30, 2013 | 6.831M |
| June 30, 2013 | 8.624M |
| March 31, 2013 | 7.322M |
| December 31, 2012 | 10.60M |
| September 30, 2012 | 14.19M |
| June 30, 2012 | 15.65M |
| March 31, 2012 | 16.35M |
| December 31, 2011 | 15.55M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
8.274M
Minimum
Jun 2019
21.82M
Maximum
Sep 2022
13.81M
Average
12.42M
Median
Research and Development Expense (Quarterly) Benchmarks
| Avidity Biosciences Inc | 52.82M |
| Taysha Gene Therapies Inc | 12.68M |
| Janux Therapeutics Inc | 12.24M |
| Tango Therapeutics Inc | 31.34M |
| 2seventy bio Inc | 51.22M |